Yu Sung Hyun, Choi Seung Joon, Noh HeeYeon, Lee In Seon, Park So Hyun, Kim Se Jong
Taehan Yongsang Uihakhoe Chi. 2021 Jul;82(4):876-888. doi: 10.3348/jksr.2020.0085. Epub 2021 Mar 22.
The aim of this study was to compare the diameter and volume of liver metastases on CT images in relation to overall survival and tumor response in patients with gastric cancer liver metastases (GCLM) treated with chemotherapy.
We recruited 43 patients with GCLM who underwent chemotherapy as a first-line treatment. We performed a three-dimensional quantification of the metastases for each patient. An independent survival analysis using the Response Evaluation Criteria in Solid Tumors (RECIST) was performed and compared to volumetric measurements. Overall survival was evaluated using Kaplan-Meier analysis and compared using Cox proportional hazard ratios following univariate analyses.
When patients were classified as responders or non-responders based on volumetric criteria, the median overall survival was 23.6 months [95% confidence interval (CI), 8.63-38.57] and 7.6 months (95% CI, 3.78-11.42), respectively ( = 0.039). The volumetric analysis and RECIST of the non-progressing and progressing groups showed similar results based on the Kaplan-Meier method ( = 0.006) and the Cox proportional hazard model ( = 0.008).
Volumetric assessment of liver metastases could be an alternative predictor of overall survival for patients with GCLM treated with chemotherapy.
本研究旨在比较接受化疗的胃癌肝转移（GCLM）患者CT图像上肝转移灶的直径和体积与总生存期及肿瘤反应之间的关系。
我们招募了43例接受一线化疗的GCLM患者。对每位患者的转移灶进行三维定量分析。采用实体瘤疗效评价标准（RECIST）进行独立生存分析，并与体积测量结果进行比较。采用Kaplan-Meier分析评估总生存期，并在单因素分析后使用Cox比例风险比进行比较。
根据体积标准将患者分为反应者和无反应者时，中位总生存期分别为23.6个月[95%置信区间（CI），8.63 - 38.57]和7.6个月（95% CI，3.78 - 11.42）（P = 0.039）。基于Kaplan-Meier方法（P = 0.006）和Cox比例风险模型（P = 0.008），非进展组和进展组的体积分析与RECIST结果相似。
对于接受化疗的GCLM患者，肝转移灶的体积评估可能是总生存期的另一种预测指标。
